FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3014748351> ?p ?o ?g. }

• W3014748351 endingPage "e000398" @default.
• W3014748351 startingPage "e000398" @default.
• W3014748351 abstract "As the field of cancer immunotherapy continues to advance at a fast pace, treatment approaches and drug development are evolving rapidly to maximize patient benefit. New agents are commonly evaluated for activity in patients who had previously received a programmed death receptor 1 (PD-1)/programmed death-ligand 1 (PD-L1) inhibitor as standard of care or in an investigational study. However, because of the kinetics and patterns of response to PD-1/PD-L1 blockade, and the lack of consistency in the clinical definitions of resistance to therapy, the design of clinical trials of new agents and interpretation of results remains an important challenge. To address this unmet need, the Society for Immunotherapy of Cancer convened a multistakeholder taskforce—consisting of experts in cancer immunotherapy from academia, industry, and government—to generate consensus clinical definitions for resistance to PD-(L)1 inhibitors in three distinct scenarios: primary resistance, secondary resistance, and progression after treatment discontinuation. The taskforce generated consensus on several key issues such as the timeframes that delineate each type of resistance, the necessity for confirmatory scans, and identified caveats for each specific resistance classification. The goal of this effort is to provide guidance for clinical trial design and to support analyses of emerging molecular and cellular data surrounding mechanisms of resistance." @default.
• W3014748351 created "2020-04-10" @default.
• W3014748351 creator A5000768609 @default.
• W3014748351 creator A5001175430 @default.
• W3014748351 creator A5007198397 @default.
• W3014748351 creator A5008479799 @default.
• W3014748351 creator A5008790176 @default.
• W3014748351 creator A5011114578 @default.
• W3014748351 creator A5011325668 @default.
• W3014748351 creator A5011776853 @default.
• W3014748351 creator A5017229890 @default.
• W3014748351 creator A5022594161 @default.
• W3014748351 creator A5031310463 @default.
• W3014748351 creator A5034692104 @default.
• W3014748351 creator A5035471137 @default.
• W3014748351 creator A5045409088 @default.
• W3014748351 creator A5048698138 @default.
• W3014748351 creator A5052980036 @default.
• W3014748351 creator A5056629382 @default.
• W3014748351 creator A5065218418 @default.
• W3014748351 creator A5066301151 @default.
• W3014748351 creator A5069425402 @default.
• W3014748351 creator A5070669850 @default.
• W3014748351 creator A5072502166 @default.
• W3014748351 creator A5074861706 @default.
• W3014748351 creator A5084822027 @default.
• W3014748351 creator A5086074491 @default.
• W3014748351 date "2020-03-01" @default.
• W3014748351 modified "2023-10-17" @default.
• W3014748351 title "Defining tumor resistance to PD-1 pathway blockade: recommendations from the first meeting of the SITC Immunotherapy Resistance Taskforce" @default.
• W3014748351 cites W1915043848 @default.
• W3014748351 cites W2010121426 @default.
• W3014748351 cites W2028697741 @default.
• W3014748351 cites W2100158834 @default.
• W3014748351 cites W2106747061 @default.
• W3014748351 cites W2112602910 @default.
• W3014748351 cites W2118982164 @default.
• W3014748351 cites W2160834915 @default.
• W3014748351 cites W2329974159 @default.
• W3014748351 cites W2373606074 @default.
• W3014748351 cites W2465860350 @default.
• W3014748351 cites W2557336488 @default.
• W3014748351 cites W2560635244 @default.
• W3014748351 cites W2587048937 @default.
• W3014748351 cites W2592144107 @default.
• W3014748351 cites W2745624257 @default.
• W3014748351 cites W2752227448 @default.
• W3014748351 cites W2767395146 @default.
• W3014748351 cites W2784235889 @default.
• W3014748351 cites W2787615428 @default.
• W3014748351 cites W2791483720 @default.
• W3014748351 cites W2792699081 @default.
• W3014748351 cites W2794408630 @default.
• W3014748351 cites W2797309423 @default.
• W3014748351 cites W2805968856 @default.
• W3014748351 cites W2810879984 @default.
• W3014748351 cites W2899537551 @default.
• W3014748351 cites W2902968854 @default.
• W3014748351 cites W2941142378 @default.
• W3014748351 cites W2944102963 @default.
• W3014748351 cites W2946126594 @default.
• W3014748351 cites W2955181150 @default.
• W3014748351 cites W2955839328 @default.
• W3014748351 cites W2963476376 @default.
• W3014748351 cites W2963686803 @default.
• W3014748351 doi "https://doi.org/10.1136/jitc-2019-000398" @default.
• W3014748351 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/7174063" @default.
• W3014748351 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/32238470" @default.
• W3014748351 hasPublicationYear "2020" @default.
• W3014748351 type Work @default.
• W3014748351 sameAs 3014748351 @default.
• W3014748351 citedByCount "108" @default.
• W3014748351 countsByYear W30147483512020 @default.
• W3014748351 countsByYear W30147483512021 @default.
• W3014748351 countsByYear W30147483512022 @default.
• W3014748351 countsByYear W30147483512023 @default.
• W3014748351 crossrefType "journal-article" @default.
• W3014748351 hasAuthorship W3014748351A5000768609 @default.
• W3014748351 hasAuthorship W3014748351A5001175430 @default.
• W3014748351 hasAuthorship W3014748351A5007198397 @default.
• W3014748351 hasAuthorship W3014748351A5008479799 @default.
• W3014748351 hasAuthorship W3014748351A5008790176 @default.
• W3014748351 hasAuthorship W3014748351A5011114578 @default.
• W3014748351 hasAuthorship W3014748351A5011325668 @default.
• W3014748351 hasAuthorship W3014748351A5011776853 @default.
• W3014748351 hasAuthorship W3014748351A5017229890 @default.
• W3014748351 hasAuthorship W3014748351A5022594161 @default.
• W3014748351 hasAuthorship W3014748351A5031310463 @default.
• W3014748351 hasAuthorship W3014748351A5034692104 @default.
• W3014748351 hasAuthorship W3014748351A5035471137 @default.
• W3014748351 hasAuthorship W3014748351A5045409088 @default.
• W3014748351 hasAuthorship W3014748351A5048698138 @default.
• W3014748351 hasAuthorship W3014748351A5052980036 @default.
• W3014748351 hasAuthorship W3014748351A5056629382 @default.
• W3014748351 hasAuthorship W3014748351A5065218418 @default.
• W3014748351 hasAuthorship W3014748351A5066301151 @default.
• W3014748351 hasAuthorship W3014748351A5069425402 @default.
• W3014748351 hasAuthorship W3014748351A5070669850 @default.

• next